Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.

Conclusions: ODX is not cost-effective for women with clinical low-risk breast cancer, which constitutes most patients with ER-positive disease.
PMID: 30659128 [PubMed - in process]

Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 21, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research